Cargando…
Relationship between long non-coding RNA PCAT-1 expression and gefitinib resistance in non-small-cell lung cancer cells
BACKGROUND: Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has been used as first-line treatment for advanced non-small-cell lung cancer (NSCLC). However, during treatment, cancer cells often develop resistance to gefitinib, the mechanisms of which are not fully understood...
Autores principales: | Wang, Shaojia, Liu, Chao, Lei, Qing, Wu, Zhengwei, Miao, Xiangshuai, Zhu, Debing, Yang, Xu, Li, Na, Tang, Mingwei, Chen, Yan, Wang, Weiwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114512/ https://www.ncbi.nlm.nih.gov/pubmed/33980216 http://dx.doi.org/10.1186/s12931-021-01719-7 |
Ejemplares similares
-
Expression Analysis of Long Non-Coding PCAT-1in Breast Cancer
por: Sarrafzadeh, Shaghayegh, et al.
Publicado: (2017) -
Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011) -
PCAT-1: A Novel Oncogenic Long Non-Coding RNA in Human Cancers
por: Xiong, Tiefu, et al.
Publicado: (2019) -
The Long Non-Coding RNA PCAT-1 Promotes Prostate Cancer Cell Proliferation through cMyc()()
por: Prensner, John R., et al.
Publicado: (2014) -
Relationship between miR-7 expression and treatment outcomes with gefitinib in non-small cell lung cancer
por: Mou, Kun, et al.
Publicado: (2016)